课题基金 / 基金详情

Clinicopathologic impact of genetic aberrations in gastrointestinal lymphoma

Clinicopathologic impact of genetic aberrations in gastrointestinal lymphoma
遗传畸变对胃肠道淋巴瘤的临床病理影响
批准号:
20590744
负责人:
NAKAMURA Shotaro
金额:
$2.91万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2008
资助国家:
日本
项目状态:
已结题
起止时间:
2008 至 2010

项目摘要

项目成果

NAKAMURA Shotaro的其他基金

相似基金

相关文献

中文摘要
翻译
背景:60-90%的淋巴结滤泡性淋巴瘤(FL)存在染色体易位t(14;18)(q32;q21)/IGH-BCL 2。方法与结果:48例胃肠道FL患者的临床病理和分子特征进行了研究。受累部位为十二指肠(54%),空肠(52%),回肠(52%),胃(29%)和结直肠(15%)。间期荧光原位杂交检测t(14;18)39例(81%)。在t(14;18)阳性组中,多部位受累(69% vs. 0%)、淋巴瘤性息肉病型表现(72% vs. 22%)和组织学分级1或2级(92% vs. 56%)比阴性组更常见。此外,t(14;18)阳性组的完全缓解率低于阴性组(56% vs. 100%,P=0.018),前者的无事件生存率有下降趋势(P=0.089)。结论:t(14;18)/IGH-BCL 2在胃肠道滤泡性淋巴瘤中较常见。这种易位可能是不良临床过程的预测因子。
英文摘要
Background : Chromosomal translocation t(14;18)(q32;q21)/IGH-BCL2 is found in 60-90% of nodal follicular lymphomas (FL). The prevalence and clinical significance of the translocation have not been examined in gastrointestinal FL. Methods & Results : Clinicopathologic and molecular features were investigated in 48 patients with gastrointestinal FL. The site of involvement was the duodenum (54%), the jejunum (52%), the ileum (52%), the stomach (29%), and the colorectum (15%). t(14;18) was detected in 39 (81%) cases by the interphase fluorescence in situ hybridization. The involvement of multiple sites (69% vs. 0%), a manifestation of lymphomatous polyposis type (72% vs. 22%) and a histological grade of 1 or 2 (92% vs. 56%) were more frequent in the t(14;18)-positive group than in the negative group. In addition, the rate of complete remission was lower in the t(14;18)-positive group than in the negative group (56% vs. 100%, P=0.018) with a trend towards poorer event-free survival in the former group (P=0.089). Conclusions : t(14;18)/IGH-BCL2 occurs frequently in gastrointestinal follicular lymphomas. This translocation may be a predictor for the adverse clinical course.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
胃MALTリンパ腫の遺伝子異常と化学療法の長期予後
胃MALT淋巴瘤的基因异常与化疗的长期预后
DOI: --
发表时间: 2009
期刊: Helicobacter Research 13
影响因子: --
作者: [中村昌太郎, 他]
通讯作者:
胃MALTリンパ腫に対するH.Pylori除菌治療:遺伝子異常と長期予後を含めて
胃MALT淋巴瘤的幽门螺杆菌根除治疗:包括遗传异常和长期预后
DOI: --
发表时间: 2009
期刊:
影响因子: --
作者: [梁井俊一, 中村昌太郎, 松本主之, 飯田三雄, 他]
通讯作者:
いきなり名医!ピロリ菌除菌治療A to Z
突然出现了一位伟大的医生根除幽门螺杆菌治疗A to Z
DOI: --
发表时间: 2010
期刊:
影响因子: --
作者: [中村昌太郎, 他]
通讯作者:
Helicobacter pylori陽性胃MALTリンパ腫の内視鏡診断
幽门螺杆菌阳性胃MALT淋巴瘤的内镜诊断
DOI: --
发表时间: 2010
期刊: Helicobacter Research 14
影响因子: --
作者: [Tanaka H, et al, 中寸昌太郎,松本主之]
通讯作者: 中寸昌太郎,松本主之
66
    Expression of CARD11 (CARMA1) and efficacy of non-surgical treatment in gastric MALT lymphoma
    • 批准号:
      16590602
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.47万
    • 财政年份:
      2004
    • 负责人:
      NAKAMURA Shotaro
    • 依托单位:
    海外基金